An open label international multi-center phase 2 activity and safety study of SU011248 [sunitinib] in patients with unresectable hepatocellular carcinoma.

Next Previous
Trial Profile

An open label international multi-center phase 2 activity and safety study of SU011248 [sunitinib] in patients with unresectable hepatocellular carcinoma.

Completed
Phase of Trial: Phase II

Latest Information Update: 02 Jun 2011

At a glance

  • Drugs Sunitinib (Primary)
  • Indications Liver cancer
  • Focus Biomarker; Therapeutic Use

    • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 17 Dec 2009 Actual patient number (37) added as reported by ClinicalTrials.gov.
    • 17 Dec 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top